Aspen targets 1mn patents in 2024, 4mn patents in 2026

Aspen’s latest agreement with Novo Nordisk, will allow for the local production of human insulin at its eastern cape-based sterile facility, aiming to supply vials to 4 million patients across Africa by 2026. The agreement also allows for critical technology and skills transfer to the region. Joining CNBC Africa for more is Stephen Saad, CEO, Aspen.